Tracking adverse drug reactions and medication errors in the Central Chronic Medicine Dispensing and Distribution (CCMDD) programme in South Africa
Conclusion: About one in seven patients reported ADRs under TLD. Medication errors were low, possibly due to effective quality control measures and stable patients being on the programme. Knowing the frequency of ADRs and medication errors is critical for enhancing the CCMDD programme. (Source: Southern African Journal of HIV Medicine)
Source: Southern African Journal of HIV Medicine - May 19, 2022 Category: African Health Authors: Kennedy Otwombe Source Type: research
Antiretroviral therapy uptake and predictors of virological failure in patients with HIV receiving first-line and second-line regimens in Johannesburg, South Africa: a retrospective cohort data analysis
Conclusion
Patients on first-line regimens had higher VL suppression rates and were more likely to remain in care than those on a second-line regimen. Being younger and having low CD4 cell counts were associated with poor outcomes, suggesting priority groups for ART adherence support. (Source: BMJ Open)
Source: BMJ Open - April 15, 2022 Category: General Medicine Authors: Gumede, S. B., Venter, F., de Wit, J., Wensing, A., Lalla-Edward, S. T. Tags: Open access HIV/AIDS Source Type: research
Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages
We report that Triumeq skewed alternative MDMs toward an inflammatory nonsenescent phenotype. Both Atripla and Triumeq caused mitochondrial dysfunction, specifically efavirenz and abacavir. Additionally, transcriptome sequencing (RNA-seq) demonstrated that both Atripla and Triumeq caused differential regulation of genes involved in immune regulation and cell cycle and DNA repair. Collectively, our data demonstrate that cART, independent of HIV, alters the MDM phenotype. This suggests that cART may contribute to cell dysregulation in PLWH that subsequently results in increased susceptibility to comorbidities.PMID:35293780 |...
Source: Antimicrobial Agents and Chemotherapy - March 16, 2022 Category: Microbiology Authors: Jennillee Wallace Hemil Gonzalez Reshma Rajan Srinivas D Narasipura Amber K Virdi Arnold Z Olali Ankur Naqib Zarema Arbieva Mark Maienschein-Cline Lena Al-Harthi Source Type: research
Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages
We report that Triumeq skewed alternative MDMs toward an inflammatory nonsenescent phenotype. Both Atripla and Triumeq caused mitochondrial dysfunction, specifically efavirenz and abacavir. Additionally, transcriptome sequencing (RNA-seq) demonstrated that both Atripla and Triumeq caused differential regulation of genes involved in immune regulation and cell cycle and DNA repair. Collectively, our data demonstrate that cART, independent of HIV, alters the MDM phenotype. This suggests that cART may contribute to cell dysregulation in PLWH that subsequently results in increased susceptibility to comorbidities.PMID:35293780 |...
Source: Antimicrobial Agents and Chemotherapy - March 16, 2022 Category: Microbiology Authors: Jennillee Wallace Hemil Gonzalez Reshma Rajan Srinivas D Narasipura Amber K Virdi Arnold Z Olali Ankur Naqib Zarema Arbieva Mark Maienschein-Cline Lena Al-Harthi Source Type: research
Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages
We report that Triumeq skewed alternative MDMs toward an inflammatory nonsenescent phenotype. Both Atripla and Triumeq caused mitochondrial dysfunction, specifically efavirenz and abacavir. Additionally, transcriptome sequencing (RNA-seq) demonstrated that both Atripla and Triumeq caused differential regulation of genes involved in immune regulation and cell cycle and DNA repair. Collectively, our data demonstrate that cART, independent of HIV, alters the MDM phenotype. This suggests that cART may contribute to cell dysregulation in PLWH that subsequently results in increased susceptibility to comorbidities.PMID:35293780 |...
Source: Antimicrobial Agents and Chemotherapy - March 16, 2022 Category: Microbiology Authors: Jennillee Wallace Hemil Gonzalez Reshma Rajan Srinivas D Narasipura Amber K Virdi Arnold Z Olali Ankur Naqib Zarema Arbieva Mark Maienschein-Cline Lena Al-Harthi Source Type: research
Immunologic Change over 72 Weeks following Raltegravir- vs Efavirenz-based Therapy in HIV/HCV co-infected Individuals in Vietnam
CONCLUSIONS: The initiation of ART in HIV/HCV co-infected individuals is associated with incomplete improvement in monocyte and T cell immune activation and exhaustion, which was associated with some corresponding improvement in liver fibrosis.PMID:34861767 | DOI:10.1089/AID.2021.0076 (Source: Cell Research)
Source: Cell Research - December 4, 2021 Category: Cytology Authors: Cecilia Shikuma Thuy Le Thao Vu Phuong Glen M Chew Van Vinh Chau Nguyen Trieu Ly Vo Chathura Siriwardhana Dominic Chow Hayk Ghukasyan Nath Limpruttdham Thomas Premeaux Louie Mar A Gangcuangco Robert H Paul Lishomwa C Ndhlovu Source Type: research
Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis
Conclusion: 3-drug regimens containing INI demonstrate better efficacy and safety than those containing RPV or EFV. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - July 21, 2021 Category: Drugs & Pharmacology Source Type: research
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Publication date: 3–9 April 2021Source: The Lancet, Volume 397, Issue 10281Author(s): Shahin Lockman, Sean S Brummel, Lauren Ziemba, Lynda Stranix-Chibanda, Katie McCarthy, Anne Coletti, Patrick Jean-Philippe, Ben Johnston, Chelsea Krotje, Lee Fairlie, Risa M Hoffman, Paul E Sax, Sikhulile Moyo, Nahida Chakhtoura, Jeffrey SA Stringer, Gaerolwe Masheto, Violet Korutaro, Haseena Cassim, Blandina T Mmbaga, Esau João (Source: The Lancet)
Source: The Lancet - April 2, 2021 Category: General Medicine Source Type: research
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era
Conclusions:
There is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; we observed greater gain among PLWH taking newer integrase strand transfer inhibitors (DTG, BIC) and DRV-based regimens. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - February 12, 2021 Category: Infectious Diseases Tags: Clinical Science Source Type: research
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Publication date: October 2020Source: The Lancet HIV, Volume 7, Issue 10Author(s): Willem D F Venter, Simiso Sokhela, Bryony Simmons, Michelle Moorhouse, Lee Fairlie, Nkuli Mashabane, Celicia Serenata, Godspower Akpomiemie, Masebole Masenya, Ambar Qavi, Nomathemba Chandiwana, Kaitlyn McCann, Shane Norris, Matthew Chersich, Gary Maartens, Samanta Lalla-Edward, Alinda Vos, Polly Clayden, Elaine Abrams, Natasha Arulappan (Source: The Lancet HIV)
Source: The Lancet HIV - October 1, 2020 Category: Infectious Diseases Source Type: research
Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis
Conclusion:
Of the ART regimens assessed in RCTs in pregnancy, LPV/r-containing regimens were associated with the highest risks of adverse perinatal outcomes. (Source: AIDS)
Source: AIDS - August 13, 2020 Category: Infectious Diseases Tags: EPIDEMIOLOGY AND SOCIAL Source Type: research
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression
Publication date: Available online 7 July 2020Source: Journal of Microbiology, Immunology and InfectionAuthor(s): Wei-Chieh Huang, Chun-Kai Huang, Sung-Hsi Huang, Shu-Wen Lin, Shyh-Tyan Ou, Yi-Ting Chen, Ya-Wen Chen, Shu-Yuan Chang, Wen-Chun Liu, Hsin-Yun Sun, Chien-Ching Hung (Source: Journal of Microbiology, Immunology and Infection)
Source: Journal of Microbiology, Immunology and Infection - July 7, 2020 Category: Microbiology Source Type: research
Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.
CONCLUSIONS: Among patients newly prescribed ART, STR initiators were significantly less likely to discontinue therapy and had greater adherence and persistence compared to MTR initiators. Regimens containing FTC/TAF as a backbone had higher persistence than those consisting of other backbones.
PMID: 32238169 [PubMed - in process] (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - March 31, 2020 Category: Infectious Diseases Authors: Cohen J, Beaubrun A, Bashyal R, Huang A, Li J, Baser O Tags: AIDS Res Ther Source Type: research
Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy
Conclusions: Viral rebound was slow following cessation of EFV/FTC/TDF in the postpartum period. Use of an FTC/TDF tail after stopping EFV was associated with the lower prevalence of subsequent NNRTI drug resistance mutation. (Source: Southern African Journal of HIV Medicine)
Source: Southern African Journal of HIV Medicine - January 26, 2020 Category: African Health Authors: Globahan Ajibola Source Type: research
Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz: An Open-label, randomized Controlled Trial.
CONCLUSION: Vitamin D2 and calcium supplements should be considered for HIV-infected patients receiving TDF/FTC/EFV in a resource-limited setting where there are limited ART options (Clinicaltrials.gov NCT0287643).
PMID: 31906840 [PubMed - as supplied by publisher] (Source: Current HIV Research)
Source: Current HIV Research - January 5, 2020 Category: Infectious Diseases Authors: Boontanondha P, Nimitphong H, Musikarat S, Ragkho A, Kiertiburanakul S Tags: Curr HIV Res Source Type: research
